---
document_datetime: 2025-02-18 13:07:35
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ebvallo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: ebvallo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.537526
conversion_datetime: 2025-12-26 20:16:56.587041
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ebvallo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/11028 /202406  | Periodic Safety Update EU Single assessment - tabelecleucel                  | 16/01/2025                          | n/a                                         |                                  | PRAC Recommendation - maintenance |
| IB/0017              | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation | 17/12/2024                          | n/a                                         |                                  |                                   |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0011/G   | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol the test methods at the site is a   | 12/12/2024   |     | SmPC, Annex II and PL   | product and any of   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|-------------------------|----------------------|
| IB/0015/G   | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 10/12/2024   |     | SmPC                    |                      |
| IB/0016/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 04/12/2024   | n/a |                         |                      |

<div style=\"page-break-after: always\"></div>

|                     | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation   |            |     |                                                                                                               |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------|
| IB/0014/G           | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                           | 23/10/2024 | n/a |                                                                                                               |
| IB/0013             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                   | 16/09/2024 | n/a |                                                                                                               |
| PSUSA/11028 /202312 | Periodic Safety Update EU Single assessment - tabelecleucel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 11/07/2024 | n/a | PRAC Recommendation - maintenance                                                                             |
| S/0008              | First annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 30/05/2024 | n/a | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                    | submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Ebvallo should be maintained.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0010             | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                          | 04/03/2024 |            | SmPC               |                                                                                                                                                      |
| PSUSA/11028 /202306 | Periodic Safety Update EU Single assessment - tabelecleucel                                                                                                                                                                                                                                                                                                                                                            | 11/01/2024 | n/a        |                    | PRAC Recommendation - maintenance                                                                                                                    |
| IB/0007             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                    | 19/12/2023 | 22/02/2024 | SmPC and Labelling |                                                                                                                                                      |
| IB/0003             | B.II.e.3.b - Change in test procedure for the immediate packaging of the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                      | 04/05/2023 | n/a        |                    |                                                                                                                                                      |
| IB/0004/G           | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation | 03/05/2023 | n/a        |                    |                                                                                                                                                      |
| IAIN/0002           | B.II.b.2.c.1 - Change to importer, batch release                                                                                                                                                                                                                                                                                                                                                                       | 09/03/2023 | 22/02/2024 | Annex II and       |                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|        | arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |            |            | PL                     |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| T/0001 | Transfer of Marketing Authorisation                                                                                                                                                     | 20/01/2023 | 06/02/2023 | SmPC, Labelling and PL |